Secure Asset Management LLC Has $1.42 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Secure Asset Management LLC trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 20.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,514 shares of the company’s stock after selling 9,390 shares during the period. Secure Asset Management LLC’s holdings in Mirum Pharmaceuticals were worth $1,424,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Los Angeles Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 10.8% during the 1st quarter. Los Angeles Capital Management LLC now owns 41,836 shares of the company’s stock worth $1,051,000 after acquiring an additional 4,069 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 31.0% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 63,534 shares of the company’s stock valued at $1,596,000 after purchasing an additional 15,022 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 7.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock valued at $448,000 after purchasing an additional 1,246 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 11.7% during the 1st quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock worth $439,000 after buying an additional 1,825 shares in the last quarter. Finally, William Blair Investment Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 0.9% during the 1st quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock worth $15,757,000 after buying an additional 5,494 shares in the last quarter.

Mirum Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:MIRM opened at $39.32 on Friday. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $45.23. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The business’s 50-day moving average is $40.63 and its 200-day moving average is $33.67. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.60 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The business had revenue of $77.90 million during the quarter, compared to the consensus estimate of $75.03 million. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The company’s revenue for the quarter was up 107.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.92) earnings per share. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MIRM. Evercore ISI raised their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald raised their price target on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Friday, October 11th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Finally, Leerink Partners upped their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $56.82.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.